Home LiteratureArticle Details
PMID: 2370681 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.

Journal of virology ·Vol. 64 ·No. 8 ·1990-08-00 ·Pages 3779-91

Nara PL, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, Goudsmit J

Abstract

Emergence in two chimpanzees of human immunodeficiency virus type 1 (HIV-1) IIIB variants resistant to neutralization by the preexisting antibody is described. Viruses isolated from the HIV-1 IIIB gp120-vaccinated and -challenged animal were more resistant to neutralization by the chimpanzee's own serum than viruses isolated from the naive infected animal, indicating immune pressure as the selective mechanism. However, all reisolated viruses were 16- to 256-fold more neutralization resistant than the inoculum virus to antibodies binding to the third variable domain (V3) of the HIV-1 external envelope. Early chimpanzee serum samples that neutralized the inoculum strain but not the reisolated viruses were found to bind an HIV-1 IIIB common nonapeptide (IQRGPGRAF) derived from the gp120 isolate-specific V3 domain shown to induce isolate-specific neutralization in other animals. Amplification of the V3 coding sequence by polymerase chain reaction and subsequent sequence analysis of the neutralization-resistant variants obtained from in vivo-infected animals indicated that early resistance to neutralization by an HIV-1 IIIB monoclonal antibody (0.5 beta) was conferred by changes outside the direct binding site for the selective neutralizing antibody. The reisolated neutralization-resistant isolates consisted of the lower-replication-competent virus subpopulations of the HIV-1 IIIB stock, as confirmed by biological and sequence analyses. In vitro passage of the HIV-1 IIIB stock through chimpanzee and human peripheral blood mononuclear cell cultures void of HIV-specific antibody resulted in homogenic amplification of the more-replication-competent subpopulation preexisting in the original viral stock, suggesting a role for the immune system in suppressing the more-replication-competent viruses.

MeSH Terms
Acquired Immunodeficiency Syndrome/immunology Amino Acid Sequence Animals Antibodies, Monoclonal Base Sequence Genetic Variation HIV Antibodies/immunology HIV Envelope Protein gp120/administration & dosage,genetics,immunology HIV Seropositivity HIV-1/genetics,immunology,isolation & purification Molecular Sequence Data Neutralization Tests Oligonucleotide Probes Oligopeptides/chemical synthesis Pan troglodytes Polymerase Chain Reaction/methods Viral Vaccines/administration & dosage
Chemicals
Antibodies, Monoclonal HIV Antibodies HIV Envelope Protein gp120 Oligonucleotide Probes Oligopeptides Viral Vaccines
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Nara P L
National Cancer Institute, Frederick Cancer Research Facility, Maryland 21701-1013.
Smit L
Dunlop N
Hatch W
Merges M
Waters D
Kelliher J
Gallo R C
Fischinger P J
Goudsmit J
References (53)
53 references, click to expand
  1. DNA sequencing with chain-terminating inhibitors.
    Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 PMID: 271968
  2. Type-restricted neutralization of molecular clones of human immunodeficiency virus.
    Science. 1988 Jul 15;241(4863):357-9 PMID: 3388046
  3. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS.
    Science. 1984 Nov 2;226(4674):549-52 PMID: 6093251
  4. Infection of chimpanzees with lymphadenopathy-associated virus.
    Lancet. 1984 Dec 1;2(8414):1276-7 PMID: 6150305
  5. Infection of chimpanzees by human T-lymphotropic retroviruses in brain and other tissues from AIDS patients.
    Lancet. 1985 Jan 5;1(8419):55-6 PMID: 2856985
  6. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection.
    J Virol. 1986 Jan;57(1):71-80 PMID: 3001367
  7. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome.
    J Virol. 1986 Apr;58(1):116-24 PMID: 3005641
  8. Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence.
    J Virol. 1986 Jul;59(1):37-44 PMID: 3012120
  9. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.
    Science. 1986 Jun 20;232(4757):1548-53 PMID: 3012778
  10. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection.
    Lancet. 1986 Jul 26;2(8500):177-80 PMID: 2873436
  11. Pathogenesis of lentivirus infections.
    Nature. 1986 Jul 10-16;322(6075):130-6 PMID: 2425264
  12. Isolation of variants of lymphocytopathic retroviruses from the peripheral blood and cerebrospinal fluid of patients with ARC or AIDS.
    J Med Virol. 1986 Aug;19(4):335-44 PMID: 2427649
  13. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.
    Lancet. 1986 Sep 20;2(8508):660-2 PMID: 2429124
  14. In vitro generation of an HTLV-III variant by neutralizing antibody.
    J Immunol. 1986 Nov 15;137(10):3306-9 PMID: 3639908
  15. Variable and conserved neutralization antigens of human immunodeficiency virus.
    Nature. 1986 Dec 11-17;324(6097):572-5 PMID: 2431324
  16. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.
    Science. 1986 Dec 12;234(4782):1392-5 PMID: 2431482
  17. Induction of anti-HIV neutralizing antibodies by synthetic peptides.
    EMBO J. 1986 Nov;5(11):3065-71 PMID: 3466790
  18. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1986 Dec;83(24):9709-13 PMID: 2432599
  19. IgG response to human immunodeficiency virus in experimentally infected chimpanzees mimics the IgG response in humans.
    J Infect Dis. 1987 Feb;155(2):327-31 PMID: 3492573
  20. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.
    J Virol. 1987 Jun;61(6):2024-8 PMID: 2437327
  21. HIV antigenaemia and virus isolation from plasma during primary HIV infection.
    Lancet. 1987 Jun 6;1(8545):1317-8 PMID: 2884436
  22. Intra-blood-brain barrier synthesis of human immunodeficiency virus antigen and antibody in humans and chimpanzees.
    Proc Natl Acad Sci U S A. 1987 Jun;84(11):3876-80 PMID: 3473487
  23. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.
    Nature. 1987 Aug 20-26;328(6132):721-3 PMID: 3475581
  24. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    J Virol. 1987 Oct;61(10):3173-80 PMID: 2442411
  25. Natural feline leukemia virus variant escapes neutralization by a monoclonal antibody via an amino acid change outside the antibody-binding epitope.
    J Virol. 1987 Nov;61(11):3410-5 PMID: 2444714
  26. Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning.
    J Med Virol. 1987 Sep;23(1):51-66 PMID: 2890703
  27. Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection.
    J Med Virol. 1987 Sep;23(1):67-73 PMID: 3479517
  28. T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees.
    J Virol. 1987 Dec;61(12):3804-8 PMID: 3500328
  29. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.
    Virology. 1988 Jul;165(1):209-15 PMID: 2838959
  30. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.
    J Virol. 1988 Aug;62(8):2622-8 PMID: 3392769
  31. Extensive variation of human immunodeficiency virus type-1 in vivo.
    Nature. 1988 Aug 4;334(6181):440-4 PMID: 3405290
  32. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees.
    Vaccine. 1988 Jun;6(3):229-32 PMID: 3166553
  33. Biological significance of the antibody response to HIV antigens expressed on the cell surface.
    Arch Virol. 1988;103(3-4):189-206 PMID: 3265052
  34. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.
    J Virol. 1989 May;63(5):2118-25 PMID: 2564898
  35. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
    Lancet. 1989 May 6;1(8645):983-5 PMID: 2565516
  36. Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity.
    J Gen Virol. 1989 Jun;70 ( Pt 6):1505-12 PMID: 2471813
  37. The biology of human immunodeficiency virus-1 IIIB infection in the chimpanzee: in vivo and in vitro correlations.
    J Med Primatol. 1989;18(3-4):343-55 PMID: 2760918
  38. Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120.
    J Virol. 1989 Sep;63(9):3595-600 PMID: 2547987
  39. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.
    Proc Natl Acad Sci U S A. 1987 Dec;84(23):8583-7 PMID: 3479807
  40. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
    Science. 1988 Jan 29;239(4839):487-91 PMID: 2448875
  41. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.
    AIDS Res Hum Retroviruses. 1987 Fall;3(3):283-302 PMID: 3481271
  42. Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein.
    Viral Immunol. 1987-1988;1(3):225-40 PMID: 3509947
  43. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.
    J Virol. 1989 Dec;63(12):5046-53 PMID: 2555541
  44. Characterization of HIV-1 neutralization escape mutants.
    AIDS. 1989 Dec;3(12):777-84 PMID: 2483618
  45. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    AIDS. 1990 Feb;4(2):107-12 PMID: 2328092
  46. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.
    Science. 1988 Feb 26;239(4843):1021-3 PMID: 2830667
  47. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6 PMID: 2450351
  48. Biologic features of HIV-1 that correlate with virulence in the host.
    Science. 1988 Apr 1;240(4848):80-2 PMID: 2832945
  49. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  50. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  51. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  52. Antigenic variation in lentiviral diseases.
    Annu Rev Immunol. 1988;6:139-59 PMID: 2838047
  53. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus.
    Infect Immun. 1981 Jun;32(3):1045-50 PMID: 6166562
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1990-08-00
Pages
3779-91
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC249673
Subset
IM
Grants
NCI NIH HHS · N01-CO-74102 · United States
Databases
GENBANK
M64766, M64767, M64768, M64769, M64770, M64771, M64772, M64773, M64774, M64775
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com